Vitamin A (Retinol, Isotretinoin, Tretinoin)

Overview

Vitamin A (Retinol, Isotretinoin, Tretinoin) is a fat-soluble vitamin and hormone involved in regulation of gene expression, epithelial integrity, immune function, and normal skin differentiation. In veterinary medicine, vitamin A derivatives are used in dogs and cats for treatment of hypovitaminosis A and selected dermatologic disorders.

Retinoid compounds such as isotretinoin and tretinoin may be incorporated into treatment protocols for sebaceous adenitis or primary seborrhea in dogs. Because vitamin A products can produce significant toxicity at excessive doses, careful dosing and monitoring are important during therapy.

Mechanism of Action (MOA): Vitamin A regulates cellular growth and differentiation through modulation of gene expression and serves as a cofactor in mucopolysaccharide synthesis, cholesterol synthesis, and hydroxysteroid metabolism. Retinol combines with opsin to form rhodopsin in rod cells (night vision) and iodopsin in cone cells (light and color vision). All retinoids have antiproliferative, anti-inflammatory, and immunomodulatory effects. Tretinoin is the acid form of vitamin A, while isotretinoin is an isomer of tretinoin. Retinoids influence epithelial turnover, sebaceous gland activity, keratinization, and immune responses within the skin and other tissues. Specifically, isotretinoin is a keratinization-stabilizing drug that reduces sebaceous gland size, inhibits sebaceous gland activity, and decreases sebum secretion — the rationale for its use in sebaceous adenitis.

Indications

Vitamin A and retinoid derivatives are used in dogs and cats for treatment of hypovitaminosis A and selected dermatologic disorders.

• Hypovitaminosis A: Used for treatment and correction of vitamin A deficiency states.
• Sebaceous adenitis or primary seborrhoea: Used in conjunction with other appropriate therapies for sebaceous adenitis or primary seborrhoea of Cocker Spaniels.
• Expanded isotretinoin indications: Isotretinoin also used for lamellar ichthyosis, intracutaneous cornifying epitheliomas, multiple epidermal inclusion cysts, benign pilomatrixomas, comedo syndrome in Schnauzers, and palliative therapy for epitheliotropic (cutaneous T-cell) lymphoma at 3–4 mg/kg PO once daily. In cats: feline acne 10 mg/cat (NOT mg/kg) PO once daily; also actinic keratosis, solar-induced squamous cell carcinoma, Bowen’s disease, and sebaceous adenitis.
• Expanded indications: vitamin A-responsive dermatosis (originally described in Cocker Spaniels but seen in other breeds), primary idiopathic seborrhoea, follicular disorders such as colour-dilution alopecia, and keratoacanthoma.

Dosage (Reference)

Dog

In dogs, vitamin A and retinoid derivatives are used for treatment of hypovitaminosis A and selected dermatologic disorders. Careful monitoring is important during prolonged oral therapy because excessive dosing may result in toxicity.

Cat

In cats, vitamin A supplementation is primarily used for treatment of hypovitaminosis A. Careful dosing is important because excessive vitamin A exposure may result in toxicity.

Warnings & Precautions

Vitamin A and retinoid derivatives can produce significant toxicity when administered at excessive doses or for prolonged periods. Careful dosing and monitoring are important during therapy.

• Pregnancy: Vitamin A, isotretinoin, and tretinoin are teratogenic and should not be used in pregnant animals.
• Vitamin A toxicity: Prolonged or excessive oral administration may result in hypervitaminosis A and systemic toxicity.
• Hepatotoxicity: High doses may cause liver injury; monitor liver parameters during prolonged therapy.
• Bone effects: Chronic excessive vitamin A exposure may promote calcium loss from bone and contribute to hypercalcemia.
• Keratoconjunctivitis sicca (KCS): Retinoids may alter tear film lipid composition and contribute to ocular dryness.
• Concurrent retinoid therapy: Avoid simultaneous use of oral and topical retinoid preparations because of increased toxicity risk.
• Topical administration: Avoid contact with the eyes, mouth, and mucous membranes during topical application.
• Concentrated livestock formulations: Vitamin A products intended for farm animals or horses may be excessively concentrated for dogs and cats.
• Topical drug combinations: Avoid simultaneous use with other topical medications unless compatibility is known.
• IV administration CONTRAINDICATED: IV administration is CONTRAINDICATED.anaphylactic shock and death have occurred in humans after IV administration. Parenteral doses must be given IM or SC only.
• Count ALL sources of vitamin A: Consider ALL sources of vitamin A (dietary, other supplements, topicals) when prescribing to avoid additive hypervitaminosis A. Particularly relevant in patients on multivitamins, liver-based diets, or already receiving any retinoid.
• Hypersensitivity + pre-existing hypervitaminosis A: Vitamin A is contraindicated in patients with known hypersensitivity to it and in patients already in a state of hypervitaminosis A.
• NIOSH hazardous drug — pregnant women must not handle: NIOSH classifies isotretinoin as a HAZARDOUS DRUG. Pregnant women must NOT have contact with the medication, and isotretinoin should NOT be dispensed to households with pregnant women . More broadly, women of childbearing age should not handle these medications. Counsel owners on safe handling and storage.
• Avoid in intact females + long withdrawal: systemic retinoids and vitamin A at therapeutic doses are EXTREME teratogens with an extremely long tissue washout. Do NOT use in intact females at all (not just confirmed pregnancy) because of severe and predictable teratogenicity and the very long withdrawal period.
• Avoid sunlight during isotretinoin: Avoid excessive sunlight exposure during isotretinoin therapy — UV effects on skin are enhanced by retinoids.
• Isotretinoin specific cautions: Use isotretinoin with caution in patients with pre-existing hypertriglyceridemia, severe renal disease, severe hepatic disease, or hypersensitivity to isotretinoin. Screen baseline lipids + renal + hepatic panel before starting.
• Absorption impaired in hepatic / pancreatic disease: Oral vitamin A requires pancreatic and mucosal hydrolases for absorption, so absorption is reduced in patients with impaired hepatic or pancreatic function. Consider parenteral administration in patients with chronic liver disease or exocrine pancreatic insufficiency.

Drug Interactions

Drug interactions with vitamin A and retinoid derivatives vary depending on formulation, dose, and route of administration. Careful monitoring is recommended when combined with other potentially interacting medications.

• Ciclosporin: Oral vitamin A may alter ciclosporin concentrations; serum levels should be monitored closely.
• Other retinoid products: Concurrent oral and topical retinoid therapy may increase the risk of toxicity.
• Topical dermatologic medications: Simultaneous application with other topical products may increase skin irritation or adverse reactions.
• Absorption inhibitors (cholestyramine / mineral oil / neomycin): cholestyramine, mineral oil, and neomycin all reduce oral vitamin A absorption. Separate cholestyramine and mineral oil doses by at least 2 hours.
• Anticoagulants / antiplatelets — bleeding risk: high doses of vitamin A may increase bleeding risk in patients on anticoagulants or antiplatelets: clopidogrel, heparin, and warfarin. Monitor coagulation if combined.
• Tetracyclines — pseudotumor cerebri: Tetracyclines (doxycycline, minocycline) concurrent with vitamin A / isotretinoin may cause pseudotumor cerebri (benign intracranial hypertension) — Plumb’s. Avoid this combination in dermatology cases on doxycycline.
• Isotretinoin INCREASES cyclosporine (opposite of vit A): isotretinoin may INCREASE cyclosporine concentrations — opposite direction to oral vitamin A (which may reduce them). If switching between vit A and isotretinoin in a patient on cyclosporine, recheck cyclosporine levels after the change.
• Isotretinoin + corticosteroids — osteoporosis: Concomitant corticosteroids (dexamethasone, prednis(ol)one) with isotretinoin may further increase the risk of osteoporosis. Both drugs independently promote bone loss; the combination is additive.
• Lab interference (Ehrlich’s bilirubin): Vitamin A may falsely elevate serum bilirubin when measured by Ehrlich’s reagent. Consider this before investigating “hyperbilirubinemia” in a patient on vitamin A.

Side Effects & Overdose

Side Effects

Adverse effects associated with vitamin A and retinoid therapy are generally dose-dependent and are more likely with prolonged administration or high doses.

• Skin irritation: Redness, dryness, scaling, or skin pigmentation changes may occur during topical therapy.
• Hepatotoxicity: High oral doses may result in liver injury or elevated hepatic enzymes.
• Hyperlipidemia: Increased serum lipid concentrations may develop during systemic retinoid therapy.
• Keratoconjunctivitis sicca (KCS): Altered tear film composition may contribute to ocular dryness.
• Bone and calcium abnormalities: Prolonged excessive administration may promote bone demineralization and hypercalcemia.
• GI effects: Vomiting, diarrhea, or decreased appetite may occur in some patients.
• Teratogenicity: Exposure during pregnancy may result in fetal abnormalities.
• dog chronic-toxicity cluster: the canine hypervitaminosis A symptom cluster includes localized or generalized papules with FIRM CENTERS, poor coat quality, alopecia, scaling, excessive bleeding, liver disease, and rarely keratoconjunctivitis sicca. These usually resolve after drug discontinuation.

Overdose

Excessive vitamin A or retinoid exposure may result in hypervitaminosis A and multisystem toxicity. Chronic overdosing is more commonly associated with clinically significant adverse effects than acute exposure.

• Hepatic toxicity: Progressive liver injury may occur with prolonged excessive dosing.
• Neurologic abnormalities: Lethargy, weakness, or behavioral changes may develop during severe toxicity.
• Skeletal abnormalities: Chronic toxicity may result in bone pain, stiffness, or abnormal calcium metabolism.
• Dermatologic reactions: Severe skin irritation, scaling, or mucocutaneous dryness may occur.
• Management: Treatment includes discontinuation of therapy and supportive care based on clinical signs.
• Monitoring: Liver enzymes, serum lipids, and calcium levels should be monitored in suspected toxicity cases.
• Hypersalivation — common dog isotretinoin overdose sign: hypersalivation is a common finding in dogs after isotretinoin overdose. Consider GI decontamination for acute overdoses when warranted.
• LD50 / threshold + 24-h poison consultation: oral LD50 in rats is 2000 mg/kg; chronic toxicity threshold in dogs/cats is around 10,000 units/kg/day. For any suspected overdose, recommends consulting a 24-hour poison consultation centre that specialises in veterinary toxicology.

Key Notes

Practical clinical points that help optimize the safe and effective use of vitamin A and retinoid derivatives in dogs and cats in everyday veterinary practice:

• Fat-soluble vitamin: Vitamin A accumulates within body tissues, increasing the risk of toxicity with prolonged excessive dosing.
• Retinoid responsiveness: Clinical improvement in dermatologic disorders may require several weeks of continuous therapy.
• Adjunctive dermatologic therapy: Retinoids are typically incorporated into multimodal skin management protocols rather than used as sole treatment.
• Variable patient response: Dermatologic improvement and tolerance to therapy can vary considerably between individual patients.
• Topical application technique: Applying topical retinoids to clean, dry skin may improve treatment effectiveness.
• Monitoring during long-term therapy: Periodic reassessment helps identify developing adverse effects before severe toxicity occurs.
• Oral versus topical therapy: Topical retinoids may reduce systemic exposure compared with oral administration in selected dermatologic cases.
• Give with fatty meal + 1-2 month onset: give vitamin A WITH FOOD — preferably food that is high in fat — to optimise absorption. Expect 1–2 months before any clinical improvement.
• Evidence base WEAK — set realistic expectations: The evidence base for vitamin A in canine dermatology is WEAK overall.
• Concrete monitoring schedule: on long-term therapy: Schirmer tear test every 3 weeks up to every 6–12 months (depending on dose / patient risk), and liver enzymes at baseline and every 6–12 months.